About Aerami
Aerami is a company based in Durham (United States) founded in 2010. Aerami has raised $151.1 million across 13 funding rounds from investors including Molex and Molex Ventures. Aerami operates in a competitive market with competitors including MannKind Corp, OptiNose, Impel NeuroPharma, Alexza and Qnovia, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$151.1 M (USD)
in 13 rounds
-
Latest Funding Round
$1.02 M (USD), Series B
Nov 09, 2023
-
Investors
Molex
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Aerami
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Aerami
Aerami has successfully raised a total of $151.1M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $1.02 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aerami
Aerami has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Molex and Molex Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Communication equipment manufacturer
|
Locked | Locked | Locked |
Investor details for Aerami
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aerami
Investment portfolio details for Aerami
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aerami
Detailed financials for Aerami
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aerami Comparisons
Peer comparison for Aerami
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aerami
Aerami operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, OptiNose, Impel NeuroPharma, Alexza and Qnovia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Developer of smart devices for nasal drug delivery
|
|
| Locked | Locked | Locked |
Intranasal delivery technology for CNS diseases is developed.
|
|
| Locked | Locked | Locked |
Developer of products for the treatment of acute and intermittent conditions
|
|
| Locked | Locked | Locked |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Inhalation devices for medical applications are developed by Iconovo.
|
Detailed competitors of Aerami
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aerami
Complete news archive for Aerami
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aerami
Aerami was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Aerami is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Aerami is a funded company, having raised a total of $151.1M across 13 funding rounds to date.
The company was founded in 2010 and is headquartered in Durham, United States. Operations center on the biotechnology sector, with a focus on inhaled therapeutics for severe respiratory conditions and related disorders. The pipeline includes AER-901 targeted at pulmonary arterial hypertension, AER-601 for post-prandial hyperglycemia, and AER-501 for type 1 and type 2 diabetes, among others. Development efforts address unmet needs in cardiopulmonary health.
Aerami's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.
Aerami has 2 investors. Key investors include Molex, and Molex Ventures.